Story thread · 7 reports / 7 sources
Why shareholders are suing Novo Nordisk over next-generation weight-loss drug
cnbc.com · 13d
How the coverage leans
Across 7 sources · syndicated copies counted once
Investors claim Novo Nordisk misled the market about CagriSema's tolerability, after disappointing clinical trial results wiped billions off its market cap.
First report: M&G’s Kelly Bets on Former Highflyers Like Novo to Trounce Peers — bloomberg.com, 15d
The coverage
- Novo Nordisk must face US shareholder lawsuit over CagriSema weight loss trial
reuters.com · 14d
- Novo Nordisk to face shareholder lawsuit accusing fraud over CagriSema trial
seekingalpha.com · 14d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.